Zacks Research Has Pessimistic Outlook of Zoetis Q4 Earnings

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Zacks Research dropped their Q4 2025 earnings estimates for shares of Zoetis in a report issued on Monday, November 24th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.39 for the quarter, down from their prior estimate of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis’ Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.77 EPS, Q4 2026 earnings at $1.66 EPS and Q2 2027 earnings at $1.91 EPS.

A number of other analysts have also recently weighed in on ZTS. Morgan Stanley lowered their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus reiterated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. KeyCorp began coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Trading Down 0.1%

ZTS stock opened at $127.78 on Wednesday. Zoetis has a 1-year low of $115.25 and a 1-year high of $181.85. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The business’s 50 day moving average is $136.12 and its 200-day moving average is $149.33. The firm has a market cap of $56.31 billion, a P/E ratio of 21.99, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.6%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. Avantax Advisory Services Inc. lifted its stake in shares of Zoetis by 4.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 26,777 shares of the company’s stock valued at $4,409,000 after purchasing an additional 1,076 shares during the period. Cetera Investment Advisers boosted its position in shares of Zoetis by 5.3% in the 1st quarter. Cetera Investment Advisers now owns 115,248 shares of the company’s stock worth $18,976,000 after purchasing an additional 5,788 shares during the last quarter. Assetmark Inc. grew its stake in shares of Zoetis by 2.6% during the first quarter. Assetmark Inc. now owns 23,533 shares of the company’s stock worth $3,875,000 after purchasing an additional 590 shares during the period. Finally, LPL Financial LLC increased its holdings in Zoetis by 10.2% in the first quarter. LPL Financial LLC now owns 437,304 shares of the company’s stock valued at $71,640,000 after purchasing an additional 40,453 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.